Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain

• Status: Completed
• Trial end date: 2021-03-09
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to verify the superiority of 16 weeks of MT-5547 treatment to placebo, as evidenced by the WOMAC pain score (the efficacy outcome measure), in patients with osteoarthritis of the knee or hip. Additional objectives of the study are to investigate the efficacy, safety, and pharmacokinetics of MT-5547 in long-term use.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mitsubishi Tanabe Pharma Corporation
• Treatments: Fasinumab

Criteria

Inclusion Criteria:

Additional screening criteria check may apply for qualification:

• Male and female Japanese patients, 40 years to 85 years at the time written informed consent is obtained.

• Patients who have been diagnosed with osteoarthritis (OA) of the knee or hip based on the American College of Rheumatology (ACR) criteria.

• Patients with an evaluated joint (knee or hip) with a K-L (Kellgren-Lawrence) score of ≥2 based on the X-ray test performed.

• Moderate to severe pain in the evaluated joint, defined as a WOMAC pain score of ≥4 (mean of the 5 items), on the WOMAC assessments.

• Patients who satisfy both 1) and 2) below.

1. Inadequate OA pain relief from at least 1 oral NSAID.

2. Intolerance to or inadequate OA pain relief from at least 1 opioid (including combination drugs), or unwillingness to take opioid therapy.

• Patients who agree to not change their current lifestyle (daily living activities and exercise) throughout the study.

• Patients who are able to complete post-operative follow-up for any joint replacement surgery that is performed during the study.

• Body mass index at screening ≤39.

• Patient who are able to understand and answer endpoint questions used in the study.

Exclusion Criteria:

Additional screening criteria check may apply for qualification:

• Presence of symptoms of carpal tunnel syndrome within 6 months before screening.

• Patients who cannot undergo MRI.

• Trauma to the index joint within 3 months prior to screening.

• Presence or history of inflammatory joint diseases other than OA, Paget's disease of the spine, pelvis or femur, multiple sclerosis, fibromyalgia, vertebral tumors or infections, or renal osteodystrophy.

• Presence or history, confirmed by imaging, of arthropathy, neuropathic joint arthropathy, hip dislocation, knee dislocation, extensive subchondral cyst, marked bone destruction or bone loss, or pathologic fractures.

• Autonomic neuropathy diagnosed in the assessment of autonomic nerve symptoms performed at screening, or baseline.

• Presence or history of orthostatic hypotension at the orthostatic hypotension assessments performed at screening, prerandomization, or baseline.

• Presence or history of autonomic neuropathy, diabetic neuropathy, or other peripheral neuropathy such as reflex sympathetic dystrophy at screening.

• Presence or history of chronic familial dysautonomia.

• Intolerance to naproxen.

• Systemic (excluding topical, intranasal, ophthalmic, and inhaled formulations) corticosteroids within 4 weeks prior to screening.

• Intra-articular corticosteroids in the evaluated joint within 12 weeks prior to screening, or in any other joint within 4 weeks prior to screening.

• Received an intra-articular injection of hyaluronic acid in any joint within the period specified for each medicine prior to screening.

• Resting heart rate of <50 bpm or >100 bpm at screening, or baseline.

• Presence or history of 2nd or 3rd degree heart block, 1st degree heart block with abnormal QRS, or bifascicular block by ECG assessment at screening.

• Non-compliance with the Numerical rating scale (NRS) recording (average pain on walking in the evaluated joint over 1 day) during the pre-treatment observation period.

• Women who are pregnant, breast-feeding, or may be pregnant.

• Use of an anti-Nerve growth factor (anti-NGF) antibody in the past, or apparent hypersensitivity or intolerance to anti-NGF antibodies.